Literature DB >> 8996514

Large cerebral infarction during praziquantel therapy in neurocysticercosis.

O Y Bang1, J H Heo, S A Choi, D I Kim.   

Abstract

BACKGROUND: Large cerebral infarction is a rare complication of neurocysticercosis. Endarteritis by inflammation of the leptomeninges is known to be its cause. CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy. A follow-up MRI obtained immediately after his cerebral infarction demonstrated notable decrease in the size of the cysts and more prominent enhancement around the peripheral margins of the cysts and the major vessels in comparison with the initial MRI. Cerebral angiography disclosed occlusions and narrowing of both internal carotid arteries at the supraclinoid portions, where multiple cysts were found on the MRI.
CONCLUSIONS: Findings in our patient strongly suggest that a secondary inflammation reaction caused by the destruction of the cysts might have enhanced the process of endarteritis. The possible deleterious effects of praziquantel therapy should be considered in the treatment of patients with subarachnoid cysticerci.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8996514     DOI: 10.1161/01.str.28.1.211

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  14 in total

1.  High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up.

Authors:  T Yee; J A Barakos; R T Knight
Journal:  West J Med       Date:  1999-02

2.  CT and MR imaging findings in cerebral toxocaral disease.

Authors:  E Xinou; A Lefkopoulos; M Gelagoti; A Drevelegas; A Diakou; I Milonas; A S Dimitriadis
Journal:  AJNR Am J Neuroradiol       Date:  2003-04       Impact factor: 3.825

Review 3.  Clinical symptoms, diagnosis, and treatment of neurocysticercosis.

Authors:  Hector H Garcia; Theodore E Nash; Oscar H Del Brutto
Journal:  Lancet Neurol       Date:  2014-11-10       Impact factor: 44.182

4.  The HP10 Taenia monoclonal antibody-based ELISA detects a similar protein in the vesicular fluid of Taenia hydatigena.

Authors:  Maria M Cortez; Glenda C Rojas; R Michael E Parkhouse
Journal:  Trop Anim Health Prod       Date:  2017-11-16       Impact factor: 1.559

Review 5.  Schistosomiasis in the People's Republic of China: prospects and challenges for the 21st century.

Authors:  A G Ross; A C Sleigh; Y Li; G M Davis; G M Williams; Z Jiang; Z Feng; D P McManus
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 6.  Antiparasitic treatment of neurocysticercosis - The effect of cyst destruction in seizure evolution.

Authors:  Hector H Garcia; Oscar H Del Brutto
Journal:  Epilepsy Behav       Date:  2017-06-09       Impact factor: 2.937

Review 7.  Stroke in central nervous system infections.

Authors:  Francisco Javier Carod-Artal
Journal:  Ann Indian Acad Neurol       Date:  2008-01       Impact factor: 1.714

Review 8.  Pharmacokinetic optimisation of the treatment of neurocysticercosis.

Authors:  J Sotelo; H Jung
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

9.  Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

Authors:  A Clinton White; Christina M Coyle; Vedantam Rajshekhar; Gagandeep Singh; W Allen Hauser; Aaron Mohanty; Hector H Garcia; Theodore E Nash
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

10.  Neurocysticercosis: HP10 antigen detection is useful for the follow-up of the severe patients.

Authors:  Agnès Fleury; Esperanza Garcia; Marisela Hernández; Roger Carrillo; Tzipe Govezensky; Gladis Fragoso; Edda Sciutto; Leslie J S Harrison; R Michael Evans Parkhouse
Journal:  PLoS Negl Trop Dis       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.